Blog

Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

Invizius

Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal.

 

With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.

 

The business is a spin-out from world-class research carried out at the University of Edinburgh, Scotland, and has been funded by Scottish Enterprise’s prestigious High-Growth Spinout Programme.

www.invizius.com